论文部分内容阅读
目的观察普米克令舒联合博利康尼雾化吸入治疗婴幼儿喘息性疾病的疗效。方法将286例有喘息症状(支气管哮喘除外)的婴幼儿随机分为治疗组及对照组两组,两组均给予相同的综合性治疗,治疗组加用普米克令舒联合博利康尼雾化吸入治疗,对照组加用糜蛋白酶联合地塞米松雾化吸入治疗,观察两组呼吸状态恢复正常的时间、肺部体征消失时间及住院天数,并将治疗组与对照组进行统计学对比。结果治疗组在呼吸状态恢复正常的时间、肺部体征消失时间及住院天数方面均明显优于对照组(P<0.01)。结论普米克令舒联合博利康尼雾化吸入治疗婴幼儿喘息性疾病(除外哮喘),可缩短病程,疗效确切,给药途径方便、安全有效,值得临床推广。
Objective To observe the curative effect of Pulmicort respules combined with boliconi nebulized inhalation on infantile asthmatic diseases. Methods A total of 286 infants and young children with asthmatic symptoms (except bronchial asthma) were randomly divided into two groups: treatment group and control group. Both groups were given the same comprehensive treatment. The treatment group was treated with pulmicort / Inhalation therapy, the control group plus chymotrypsin plus dexamethasone atomization inhalation treatment, the resumption of respiratory status of the two groups were observed, the time of disappearance of the lung signs and days of hospitalization, and the treatment group and the control group for statistical comparison. Results The treatment group was significantly better than the control group (P <0.01) in resuming normal breathing state, disappearing pulmonary signs and days of hospitalization. Conclusion Pulmicort respules combiblocinib aerosol inhalation in the treatment of infantile asthmatic diseases (excluding asthma), which can shorten the course of disease and have definite curative effect. The route of administration is convenient, safe and effective and worthy of clinical promotion.